Long test procedures such as cultivation on agar may soon be a thing of the...
Long test procedures such as cultivation on agar may soon be a thing of the past when testing patients for multi-resistent pathogens.

Credit: University of Cologne

Scientific breakthrough

New accelerated diagnosis of multi-resistant hospital pathogens

A team of researchers at the University of Cologne's Faculty of Medicine and the German Center for Infection Research (DZIF) use a novel immunochromatographic method to detect bacteria that are resistant to the antibiotic group carbapenemes within 20 to 45 minutes from blood cultures with 100 percent certainty.

Patients with bloodstream infections caused by gram-negative pathogens such as Escherichia coli (E. coli) have a high mortality rate. However, the infection has so far been treatable with antibiotics in most cases. But due to the increased bacterial resistance to antibiotics, including carbapenemes, therapy has become increasingly difficult. Infections with multi-resistant pathogens that are also resistant to such reserve antibiotics often lead to ineffective antibiotic therapy and thus to higher mortality.

Methods to detect antibiotic resistance take 16 to 72 hours. Accelerated diagnostics therefore comprise an essential step in treating patients with infections caused by carbapenem-resistant bacteria faster, and in curbing the spread of the pathogens. The resistance of gram-negative bacteria is usually caused by enzymes that can destroy antibiotics, including carbapenem antibiotics. They are known as carbapenemases. The most common carbapenemases worldwide are Klebsiella pneumoniae carbapenemase (KPC), New Delhi metallo-betalactamase (NDM) and OXA-48.

The present study examined blood samples mixed with carbapenemase-producing bacteria. Three of the four most common carbapenemases—OXA-48, KPC and NDM—were discovered directly from positive blood cultures using a single test procedure without the need for further time-consuming cultivation on agar plates. The new method is fast, easy to use, inexpensive (approximately 10 euros per test) and can be performed in any clinical microbiology laboratory.

"With this procedure, we have come a giant step closer to our goal of being able to help patients infected with multi-resistant pathogens as quickly as possible," said the lead author of the study, Dr. Axel Hamprecht from the German Center for Infection Research and the Institute for Medical Microbiology, Immunology and Hygiene at Cologne University Hospital. "In the case of the aggressive pathogens we are confronted with, every minute counts in order to start a targeted therapy. We now have to conduct follow-up studies in order to transfer our findings into clinical practice as quickly as possible."

The proof-of-principle study, which is funded by the University of Cologne's Faculty of Medicine, proves the safety and efficacy of the new method. However, before the new method can replace conventional diagnostics and be introduced into clinical practice, further studies will be necessary.

Source: University of Cologne

24.09.2018

Read all latest stories

Related articles

Laboratory

Partnership for molecular diagnostic test

SpeeDx Pty. Ltd., a developer of innovative molecular diagnostic solutions, has signed an agreement with Thermo Fisher Scientific, the world leader in serving science. The announcement was made at…

Antimicrobial stewardship

A diagnostic marker reduces antibiotics use

Since 2009, as part of diagnostic and antimicrobial stewardship strategies, Hampshire Hospitals National Health Service (NHS) Trust has used serum procalcitonin (PCT) – an innovative and highly…

TB and HIV disregard national borders

The World Congress for Biomedical Laboratory Science (IFBLS 2012) in Berlin yet again emphasised that infections require safe and low-cost diagnostics worldwide

Related products

Infectious diseases testing

Atlas Genetics - Atlas Genetics io system

Atlas Genetics Ltd

LIS, Middleware, POCT

i-SOLUTIONS Health - LabCentre

i-SOLUTIONS Health GmbH

Amplification/Detection

Agena Bioscience - MassARRAY Colon Panel

Agena Bioscience GmbH

Immunochemistry

Beckman Coulter - phi (Prostate Health Index)

Beckman Coulter, Inc.

Clinical chemistry

DiaSys Diagnostic Systems - InnovaStar

DiaSys Diagnostic Systems GmbH

Scanner

Hamamatsu Photonics – NanoZoomer S360

Hamamatsu Photonics Deutschland GmbH